Alloy Therapeutics ("Alloy"), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug discovery technologies, announced today that it is launching a new ...

The market is projected to grow from $11B in 2024 to $40B by 2030, driven by both conventional bispecifics and advancements such as antibody-drug ... workflow for monoclonal antibody discovery ...

Alloy Therapeutics ("Alloy"), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug ...

UCB, a global biopharmaceutical company, and XtalPi, a global leader in AI drug discovery, today announced a license ...

Hummingbird Bioscience, a precision biotherapeutics company discovering and developing transformative biologics for hard-to-treat diseases, today announced it has granted Immunome, Inc. (Nasdaq: IMNM) ...

and BRUSSELS, Jan. 9, 2025 /PRNewswire/ -- UCB, a global biopharmaceutical company, and XtalPi, a global leader in AI drug ... the entire antibody discovery and optimisation workflow," said ...

Investors sell off AMD shares despite the company's pivot to life sciences AI, following a rating downgrade by HSBC that ...

Absci recently received a $20 million PIPE investment from AMD that improves its runway and R&D platform with AI. See why I ...

Kidney cancer therapy candidate, TLX250 (177Lu-girentuximab): The Company was granted a pre-investigational new drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) in Q4 2024, to ...

Radiopharmaceuticals company Telix Pharmaceuticals has provided its Q4 FY24 trading update, showing sustained revenue growth.